

Successful VAT reclaim of £12.2 million

RNS Number : 4513B

Novacyt S.A.

22 August 2024

NOVACYT

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Successful VAT reclaim of £12.2 million

Paris, France, and Eastleigh and Manchester, UK - 22 August 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has successfully reclaimed £12.2 million in VAT from HMRC, with the full sum having been received by the Company.

As announced in the AGM Statement issued on 18 July 2024, the Group submitted a request to reclaim circa £12.2 million VAT relating to Department of Health and Social Care ("DHSC") invoices that will now not be paid following the dispute settlement reached with the DHSC.

Following settlement of the dispute, including the payment of £5.0 million to the DHSC (paid in early July), the Group's net cash position has increased by over £7.0 million.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Contacts

Novacyt SA

<https://novacyt.com/investors>

Lyn Rees, Chief Executive Officer

Via Walbrook PR

Steve Gibson, Chief Financial Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker) +44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker) +44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /
Rémi Durgetto / Yannick Petit y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or novacyt@walbrookpr.com
Stephanie Cuthbert / Paul McManus / +44 (0)7796 794 663 / +44 (0)7980 541 893
Phillip Marriage / Alice Woodings +44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical <i>in vitro</i> diagnostic products, workflows and services focused on three therapeutic areas: <ul style="list-style-type: none">· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests· Precision Medicine: DPYD genotyping assay· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: <ul style="list-style-type: none">· Ranger® Technology: automated DNA sample preparation and target enrichment technology· MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only

Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUUARRSRUWUAR